Mu-opioid receptors have been documented on cancer cells, and receptor stimulation can increase cancer progression in preclinical models, although a large retrospective study found no increased risk of cancer or cancer-related mortality in opiate dependent patients receiving buprenorphine opioid replacement therapy [44]. This evidence concerns the gene OPRM1 and cancer.